Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Sichuan Honghe Biotechnology Co., Ltd.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07138001CT.gov Phase 2 Clinical Trial of KH617 | — | Not Yet Recruiting | — | — | — |
NCT05737368CT.gov Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab | — | Unknown | — | — | — |
NCT04528680CT.gov Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma | — | Active Not Recruiting | — | — | — |
NCT04135807CT.gov Implantable Microdevice In Primary Brain Tumors | — | Recruiting | — | — | — |
NCT03672721CT.gov IA Carboplatin + Radiotherapy in Relapsing GBM | — | Recruiting | — | — | — |
NCT02684058CT.gov Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | — | Completed | — | — | — |
NCT03149575CT.gov VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM | — | Terminated | — | — | — |
NCT01317212CT.gov Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme | — | Withdrawn | — | — | — |
NCT01934361CT.gov Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | — | Completed | — | — | — |
NCT01837862CT.gov A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | — | Completed | — | — | — |
Show 6 more trialsShow fewer
NCT01778530CT.gov TRC105 for Recurrent Glioblastoma | — | Terminated | — | — | — |
NCT01564914CT.gov A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma | — | Completed | — | — | — |
NCT01386710CT.gov Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma | — | Suspended | — | — | — |
NCT00650949CT.gov Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma | — | Terminated | — | — | — |
NCT00995007CT.gov A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas | — | Completed | — | — | — |
NCT00635557CT.gov Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | Sichuan Honghe Biotechnology Co., Ltd. | P3 | BB · 66 |
| Depatuxizumab Mafodotin | AbbVie | P3 | BB |
| Cintredekin Besudotox | INSYS Therapeutics Inc | P3 | BB |
| Camustine | Leland Metheny | P3 | BB |
| (+)-Vincristine | University of Cincinnati | P3 | BB |
| Irinotecan | University of Cincinnati | P3 | BB |
| Capecitabine | Northwell Health | P2 | BB |
| Lomustine | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
| Enzastaurin | Denovo Biopharma LLC | P3 | BB |
+42 more in the Glioblastoma cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Carboplatin in Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/carboplatin-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →